Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: Findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). | Child and Adolescent Psychiatry and Mental Health BioMed Central Research Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit hyperactivity disorder Findings from a patient parent and physician perspective using items from the pediatric adverse event rating scale PAERS Peter M Wehmeier 1 Alexander Schacht1 Martin Lehmann1 Ralf W Dittmann1 2 Susan G Silva3 and John S March3 Open Access Address 1Lilly Deutschland Medical Department Bad Homburg Germany 2Department of Child and Adolescent Psychosomatic Medicine University of Hamburg Germany and 3Duke University Child and Family Study Center Duke University Medical Center Durham . USA Email Peter M Wehmeier - wehmeier_peter@ Alexander Schacht - schacht_alexander@ Martin Lehmann - lehmann_martin@ Ralf W Dittmann - dittmann_ralf_w@ Susan G Silva - silva007@ John S March - jsmarch@ Corresponding author Published 28 May 2008 Received 27 February 2008 Child and Adolescent Psychiatry and Mental Health 2008 2 11 doi 1753-2000-2- Accepted 28 May 2008 11 This article is available from http content 2 1 1 1 2008 Wehmeier et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract__ Background The objective of this analysis was to measure changes in items on the Pediatric Adverse Event Rating Scale PAERS that relate to emotional well-being of children and adolescents with Attention-Deficit Hyperactivity Disorder ADHD during treatment with atomoxetine for up to 24 weeks from the perspective of the patient the parent and the physician. Methods Patients aged 6-17 years .
